Michael J DiStefano

Dr. Michael J DiStefano


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2016 in Global Health: Science and Practice
Verified
Journal Article
Open access
PDF file
MDMichael J DiStefano
Michael J DiStefano
HSHarald Schmidt
Harald Schmidt
Promising mHealth approaches for TB treatment adherence include:

2 April 2020 in Annual Review of Public Health
Verified
Journal Article
Open access
SKSo-Yeon Kang
So-Yeon Kang
GBGe Bai
Ge Bai
MDMichael J DiStefano
Michael J DiStefano
MSMariana P. Socal
Mariana P. Socal
FYFarah Yehia
Farah Yehia
GAGerard F. Anderson
Gerard F. Anderson
The United States relies primarily on market forces to determine prices for drugs, whereas most other industrialized countries use a variety of approaches to determine drug prices. Branded drug companies have patents and market exclusivity periods in most industrialized countries. During this period, pharmaceutical companies are allowed to set their list price as high as they prefer in the United States owing to the absence of government price control mechanisms that exist in other countries. Insured patients often pay a percentage of the list price, and cost sharing creates some pressure to lower the list price. Pharmacy benefit managers negotiate with drug companies for lower prices by offering the drug company favorable formulary placement and fewer utilization controls. However, these approaches appear to be less effective, compared with other countries’ approaches to containing branded drug prices, because prices are substantially higher in the United States. Other industrialized countries employ various forms of rate setting and price regulation, such as external reference pricing, therapeutic valuation, and health technology assessment to determine the appropriate price.

1 May 2019 in Health Affairs
Verified
Journal Article
Closed access
SKSo-Yeon Kang
So-Yeon Kang
MDMichael J DiStefano
Michael J DiStefano
MSMariana P. Socal
Mariana P. Socal
GAGerard F. Anderson
Gerard F. Anderson
Many countries use external reference pricing to help determine drug prices. However, external reference pricing has received little attention in the US—perhaps because the US is often the first ad...

27 September 2023 in Health Economics, Policy and Law
Verified
Journal Article
Open access
PDF file
VCVictoria Charlton
Victoria Charlton
MDMichael J DiStefano
Michael J DiStefano
PMPolly Mitchell
Polly Mitchell
LMLiz Morrell
Liz Morrell
LRLeah Rand
Leah Rand
GWGry Wester
Gry Wester
It is acknowledged that health technology assessment (HTA) is an inherently value-based activity that makes use of normative reasoning alongside empirical evidence. But the language used to conceptualise and articulate HTA's normative aspects is demonstrably unnuanced, imprecise, and inconsistently employed, undermining transparency and preventing proper scrutiny of the rationales on which decisions are based. This paper – developed through a cross-disciplinary collaboration of 24 researchers with expertise in healthcare priority-setting – seeks to address this problem by offering a clear definition of key terms and distinguishing between the types of normative commitment invoked during HTA, thus providing a novel conceptual framework for the articulation of reasoning. Through application to a hypothetical case, it is illustrated how this framework can operate as a practical tool through which HTA practitioners and policymakers can enhance the transparency and coherence of their decision-making, while enabling others to hold them more easily to account. The framework is offered as a starting point for further discussion amongst those with a desire to enhance the legitimacy and fairness of HTA by facilitating practical public reasoning, in which decisions are made on behalf of the public, in public view, through a chain of reasoning that withstands ethical scrutiny.

1 July 2020 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Closed access
PDF file
MDMichael J DiStefano
Michael J DiStefano
CKCarleigh B. Krubiner
Carleigh B. Krubiner
When setting priorities for health, there is broad agreement that a range of social values and ethical principles beyond clinical and cost-effectiveness matter, but exactly how health technology assessment (HTA) should account for a broader set of criteria remains an area of ongoing debate. In light of this, we welcome a recent review paper by Baltussen et al. evaluating the potential of different multi-criteria decision analysis (MCDA) approaches to enable HTA agencies to incorporate a broader set of values in their appraisals. The authors describe three approaches to MCDA—qualitative MCDA, quantitative MCDA, and MCDA with decision rules—laying out their relative advantages and disadvantages and providing recommendations for how they can best be implemented. While we endorse many of the authors' assessments and conclusions, including the critical role of deliberation in any MCDA approach and the undertaking of qualitative MCDA at a minimum, we take a stronger position regarding the flaws of quantitative MCDA and strongly caution against it. We find quantitative MCDA antithetical to at least two of the ways MCDA is intended to improve HTA recommendations: (i) enhancing quality and (ii) promoting transparency. Quantitative MCDA may mask the complex tradeoffs that exist within and between decision criteria and remain generally inaccessible to those who are not well-versed in its technical methods of appraisal. We advocate for a predominantly qualitative approach to MCDA appraisal centered around deliberation and supplemented with decision aids to help account for health opportunity costs.

10 January 2019 in Global Public Health
Verified
Journal Article
Open access
JAJoseph Ali
Joseph Ali
MDMichael J DiStefano
Michael J DiStefano
IMIris Coates McCall
Iris Coates McCall
DGDustin G. Gibson
Dustin G. Gibson
GKGulam Muhammed Al Kibria
Gulam Muhammed Al Kibria
AHAdnan A Hyder
Adnan A Hyder
Active public health surveillance has traditionally been carried out through face-to-face household surveys or contact with providers, which can be time and resource intensive. The increasing ubiquity of mobile phones and availability of phone survey platforms provide an opportunity to explore the use of mobile phone surveys (MPS) for active disease and risk factor surveillance, including for non-communicable diseases (NCDs). Scholars are increasingly examining the ethics implications of mobile health (mHealth), but few have focused on the ethics of mHealth in low- and middle-income countries (LMICs), and even fewer on mHealth for active surveillance. Given that little is known about ethics-related attitudes and practices of stakeholders invested in the conduct and oversight of mHealth in LMICs, we undertook a cross-sectional global stakeholder survey of ethics-related issues implicated by active observational MPS, with a contextual frame of monitoring NCD risk factors in LMICs. We analyse these findings with an organising focus on ethical issues that arise before, during and after conduct of an MPS including defining the activity; anticipating harms and benefits; obtaining consent; data ownership, access, and use; and ensuring sustainability. Finally, we present a set of empirical, conceptual, and normative considerations that arise from this analysis and merit further consideration.